Book on hepatitis from page 500 to 507

Book on hepatitis from page 500 to 507

500  Hepatology 2012
Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing
cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to
a scoring system for the diagnosis of autoimmune hepatitis. Hepatology
1996;23:1369-76. (Abstract)
Bodenheimer Jr H, Schaffner F, Pezzullo J. Evaluation of colchicine therapy in primary biliary
cirrhosis. Gastroenterology 1998;95:124-9. (Abstract)
Bodenheimer Jr HC, Schaffner F, Sternlieb I, et al. A prospective clinical trial of D-penicillamine
in the treatment of primary biliary cirrhosis. Hepatology 1985;5:1139-42. (Abstract)
Broome U, Glaumann H, Lindstom E, et al. Natural history and outcome in 32 Swedish patients
with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002;36:586-9.
(Abstract)
Broome UO, Loof R, Bodemar L, Hultcrantz G, Danielsson R, Prytz A, et al. Natural history and
prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut
1996;38:610-5. (Abstract)
Calmus Y, Gane P, Rouger P, et al. Hepatic expression of class I and class II major
histocompatibility complex molecules in primary biliary cirrhosis: effect of
ursodeoxycholic acid. Hepatology 1990;11:12-5. (Abstract)
Cancado Elr, Porta G. Autoimmune hepatitis in South America. 2000; Kluwer Academic
Publishers, Dordrecht, Boston, London.
Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev
2003:CD003626. (Abstract)
Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of
prognosis in primary biliary cirrhosis. Final results of an international trial.
Gastroenterology 1985;89:1084-91. (Abstract)
Crivelli O, Lavarini C, Chiaberge E, et al. Microsomal autoantibodies in chronic infection with
HBsAg associated delta (delta) agent. Clin. Exp. Immunol. 1983;54:232-8. (Abstract)
Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease.
Hepatology 1998;28:360-5. (Abstract)
Czaja AJ, Carpenter HA, Santrach PJ, et al. Evidence against hepatitis viruses as important
causes of severe autoimmune hepatitis in the United States. J. Hepatol.
1993;18:342-52. (Abstract)
Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic
type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.
Hepatology 1999;30:1381-6. (Abstract)
Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune
hepatitis. Gastroenterology 2000;119:1312-6. (Abstract)
Dalekos GN, Wedemeyer H, Obermayer-Straub P, et al. Epitope mapping of cytochrome
P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon
treatment. J Hepatol 1999;30:366-75. (Abstract)
Danielson A, Prytz H. Oral budesonide for treatment of autoimmune chronic hepatitis. Aliment.
Pharmacol. Ther. 1994;8:585-90. (Abstract)
Davis Pa, Leung P, Manns M, et al. M4 and M9 antibodies in the overlap syndrome of primary
biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology
1992;16:1128-36. (Abstract)
De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. World J Gastroenterol
2009;15:1613-9. (Abstract)
Debray D, Maggiore G, Giradet JP, et al. Efficacy of cyclosporin A in children with type 2
autoimmune hepatits. J. Pediatr 1999;135:111-4. (Abstract)
Devlin J, Donaldson P, Portman B, et al. Recurrence of autoimmune hepatitis following liver
transplantation. Liver Transpl Surg 1995;1:162-5. (Abstract)
Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: refinement and
validation of survival models. Gastroenterology 1992;103:1893-1901. (Abstract)
Dienes HP, Popper H, Manns M, et al. Histologic features in autoimmune hepatitis. Z
Gastroenterol 1989;27:327-30. (Abstract)
Dighiero G, Lymberi P, Monot C, et al. Sera with high levels of anti-smooth muscle and anti-mitochondrial antibodies frequently bind to cytoskeleton proteins. Clin Exp Immunol
1990;82:52-6. (Abstract)
Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II
genes and proteins on patients with autoimmune hepatitis. Hepatology 1994;19:609-15. (Abstract)
Alcoholic Hepatitis  501
Donaldson PT. Immunogenetics in liver disease. Baillieres Clin Gastroenterol 1996;10:533-49
(Abstract)
Donaldson PT. TNF gene polymorphisms in primary biliary cirrhosis: a critical appraisal
[editorial; comment]. J Hepatol 1999;31:366-8. (Abstract)
Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment
outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002;6:419-37. (Abstract)
Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active
hepatitis: human leukocyte antigens DR 4 and A1-B8-DR-3 are independent risk
factors. Hepatology 1991;13:701-6. (Abstract)
Dubel L, Farges O, Courvalin JC, et al. Persistence of gp210 and multiple nuclear dots
antibodies does not correlate with recurrence of primary biliary cirrhosis 6 years after
liver transplantation. J Hepatol 1998;28:169-70. (Abstract)
Durazzo M, Philipp T, Van Pelt FN, et al. Heterogeneity of liver-kidney microsomal
autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology
1995;108:455-62. (Abstract)
Farrant JM, Hayllar KM, Wilkinson Ml, et al. Natural history and prognostic variables in primary
sclerosing cholangitis. Gastroenterology 1991;100:1710-7. (Abstract)
Fernandez NF, Redeker AG, Vierling JM, et al. Cyclosporine therapy in patients with steroid
resistant autoimmune hepatitis. Am. J. Gastroenterol. 1999;94:241-8. (Abstract)
Frazer IH, Mackay IR, Jordan TW, et al. Reactivity of anti-mitochondrial autoantibodies in
primary biliary cirrhosis: definition of two novel mitochondrial polypeptide
autoantigens. J Immunol 1985;135:1739-45. (Abstract)
Fujimoto M, Sato S, Ihn H, et al. Autoantibodies to pyruvate dehydrogenase complex in patients
with systemic sclerosis. Possible role of anti-E1 alpha antibody as a serologic
indicator for development of primary biliary cirrhosis. Arthritis Rheum 1995;38:985-9.
(Abstract)
Geall MG, Schoenfield LJ, Summerskill WHJ. Classification and treatment of chronic active liver
disease. Gastroenterology 1968;55:724-9. (Abstract)
Gelpi CSE, Rodriguez-Sanchez Jl. Autoantibodies against a serine tRNA-protein complex
implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci US
1992;89:9739-43. (Abstract)
Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity.
Gastroenterology 1991;100:822-33. (Abstract)
Gershwin ME, Mackay IR, Sturgess A, et al. Identification and specificity of a cDNA encoding
the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol
1987;138:3525-31. (Abstract)
Gordon MA, Oppenheim E, Camp NJ, et al. Primary biliary cirrhosis shows association with
genetic polymorphism of tumour necrosis factor alpha promoter region [see
comments]. J Hepatol 1999;31:242-. (Abstract)
Götz G, Neuhaus R, Bechstein WO, et al. Recurrence of autoimmune hepatitis after liver
transplantation. Transplant. Proc. 1999;31:430-1. (Abstract)
Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic acid
therapy for primary biliary cirrhosis: a meta analysis. Lancet 1999;354:1053-60.
(Abstract)
Gouw AS, Haagsma EB, Manns M, et al. Is there recurrence of primary biliary cirrhosis after
liver transplantation? A clinicopathologic study in long-term survivors. J Hepatol
1994;20:500-7. (Abstract)
Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis
following liver transplantation. Hepatology 1999;29:1050-6. (Abstract)
Gregorio Gv, Portman B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year
experience. Hepatology 1997;25:541-7. (Abstract)
Guenguen M, Boniface O, Bernard O, et al. Identification of the main epitope on human
cytochrome P450IID6 recognized by anti-liver kidney microsome antibody. J.
Autoimmun. 1991;4:607-15. (Abstract)
Guenguen M, Meunier-Rotival M, Bernard O, et al. Anti-liver-kidney microsome antibody
recognizes a cytochrome P450 from the IID subfamily. J. Exp. Med. 1988;168:801
(Abstract)
Haagsma EB. Clinical relevance of recurrence of primary biliary cirrhosis after liver
transplantation. Eur J Gastroenterol Hepatol 1999;11:639-42. (Abstract)
502  Hepatology 2012
Haagsma EB, Manns M, Klein R, et al. Subtypes of antimitochondrial antibodies in primary
biliary cirrhosis before and after orthotopic liver transplantation. Hepatology
1987;7:129-33. (Abstract)
Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for
patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
(Abstract)
Hendrickse MT, Rigney E, Giaffer MH, et al. Low-dose methotrexate is ineffective in primary
biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology
1999;117:400-7. (Abstract)
Heneghan MA, Mcfarlane IG. Current and novel immunosuppressive therapy for autoimmune
hepatitis. Hepatology 2002;35:7-13. (Abstract)
Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with anti
liver/kidney microsome type 1: a second type of "autoimmune" hepatitis. Hepatology
1987;7:1333-9. (Abstract)
Ikeda T, Tozuka S, Noguchi O. Effects of additional administration of colchicine in
ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective
randomized study. j Hepatol 1996;24:88-94. (Abstract)
Ishii H, Saifuku K, Namihisa T. Multiplicity of mitochondrial inner membrane antigens from beef
heart reacting with antimitochondrial antibodies in sera of patients with primary biliary
cirrhosis. Immunol Lett 1985;9:325-30. (Abstract)
Johnson PJ, Mcfarlane IG. Meeting report: International autoimmune hepatitis group.
Hepatology 1993;18:998-1005. (Abstract)
Johnson PJ, Mcfarlane IG, Williams R. Azathioprine for long-term maintenance of remission in
autoimmune hepatitis. N. Engl.J. Med. 1995;333:958-63. (Abstract)
Jones DE, Watt FE, Metcalf JV, et al. Familial primary biliary cirrhosis reassessed: a
geographically-based population study. J Hepatol 1999;30:402-7. (Abstract)
Joplin R, Wallace Ll, Johnson GD, et al. Subcellular localization of pyruvate dehydrogenase
dihydrolipoamide acetyltransferase in human intrahepatic biliary epithelial cells. J
Pathol 1995;176:381-90. (Abstract)
Joplin RE, Neuberger JM. Immunopathology of primary biliary cirrhosis. Eur J Gastroenterol
Hepatol 1999;11:587-93. (Abstract)
Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive
therapy for autoimmune hepatitis - report of three cases. Z. Gastroenterol.
1996;35:571-8. (Abstract)
Kaplan MM, Alling DW, Zimmerman HJ, et al. A prospective trial of colchicine for primary biliary
cirrhosis. N Engl J Med 1986;315:1448-54. (Abstract)
Kato Y, Suzuki K, Kumagai M, et al. Familial primary biliary cirrhosis. Immunological and
genetic study. Am J Gastroenterol 1981;75:188-91. (Abstract)
Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation.
Lancet 1998;351:409-413. (Abstract)
Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary
sclerosing cholangitis. Mayo Clin Proc 2000;75:688-94. (Abstract)
Kirk AP, Jain S, Pocock S, et al. Late results of the Royal Free Hospital prospective controlled
trial of prednisolone therapy in hepatitis B surface antigen negative chronic active
hepatitis. Gut 1980;21:7893. (Abstract)
Klein R, Berg, PA. Anti-M4 antibodies in primary biliary cirrhosis react with sulphite oxidase, an
enzyme of the mitochondrial inter-membrane space. Clin Exp Immunol 1991;84:445-8. (Abstract)
Klein R, Kloppel G, Garbe W, et al. Antimitochondrial antibody profiles determined at early
stages of primary biliary cirrhosis differentiate between a benign and a progressive
course of the disease. A retrospective analysis of 76 patients over 6-18 years. J
Hepatol 1991;12:21-7.
Klein R, Pointner H, Zilly W, et al. Antimitochondrial antibody profiles in primary biliary cirrhosis
distinguish at early stages between a benign and a progressive course: a prospective
study on 200 patients followed for 10 years. Liver 1997;17:119-28. (Abstract)
Kurki P, Miettinen A, Linder E, et al. Different types of smooth muscle antibodies in chronic
active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic
significance. Gut 1980;21:878-84. (Abstract)
Lankisch TO, Strassburg CP, Debray D, et al. Detection of autoimmune regulator gene
mutations in children with type 2 autoimmune hepatitis and extrahepatic immune-mediated diseases. J Pediatr 2005;146:839-42. (Abstract)
Alcoholic Hepatitis  503
Larusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a
workshop. Hepatology 2006;44:746-64. (Abstract)
Lassoued K, Brenard R, Degos F, et al. Antinuclear antibodies directed to a 200-kilodalton
polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and
immunological study of a series of 150 patients with primary biliary cirrhosis.
Gastroenterology 1990;99:181-6 (Abstract)
Lenzi M, Manotti P, Muratori L, et al. Liver cytosolic 1 antigen-antibody system in type 2
autoimmune hepatitis and hepatitis C virus infection. Gut 1995;36:749-54. (Abstract)
Leung PS, Chuang DT, Wynn RM, et al. Autoantibodies to BCOADC-E2 in patients with
primary biliary cirrhosis recognize a conformational epitope. Hepatology
1995;22:505-13. (Abstract)
Leung PS, Van De Water J, Coppel Rl, et al. Molecular aspects and the pathological basis of
primary biliary cirrhosis. J Autoimmun 1996;9:119-28. (Abstract)
Leuschner M, Guldutuna S, You T, et al. Ursodeoxycholic acid and prednisolone versus
ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary
cirrhosis. J Hepatol 1996;25:49-57. (Abstract)
Leuschner M, Holtmeier J, Ackermann H, et al. The influence of sulindac on patients with
primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot
study. Eur J Gastroenterol Hepatol 2002;14:1369-76. (Abstract)
Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for
treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
Gastroenterology 1999;117:918-25. (Abstract)
Lidman K, Biberfeld G, Fagraeus A, et al. Anti-actin specificity of human smooth muscle
antibodies in chronic active hepatitis. Clin Exp Immunol 1976;24:266-72. (Abstract)
Lin F, Noyer Cm, Ye Q, et al. Autoantibodies from patients with primary biliary cirrhosis
recognize a region within the nucleoplasmic domain of inner nuclear membrane
protein LBR. Hepatology 1996;23:57-61. (Abstract)
Lindenborn-Fotinos J, Baum H, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis:
species and nonspecies specific determinants of M2 antigen. Hepatology
1985;5:763-9. (Abstract)
Lohr H, Fleischer B, Gerken G, et al. Autoreactive liver-infiltrating T cells in primary biliary
cirrhosis recognize inner mitochondrial epitopes and the pyruvate dehydrogenase
complex. J Hepatol 1993;18:322-7. (Abstract)
Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary
cirrhosis: results of a long-term placebo controlled trial. Gastroenterology
1993;104:519-26. (Abstract)
Luettig B, Boeker KH, Schoessler W, et al. The antinuclear autoantibodies Sp100 and gp210
persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J
Hepatol 1998;28:824-8. (Abstract)
Mackay I, R, Taft LI, Cowling DC. Lupoid hepatitis. Lancet 1956;2:1323-6. (Abstract)
Mackay IR. Primary biliary cirrhosis showing a high titer of autoantibody. N. Engl. J. Med.
1958;258:707-13. (Abstract)
Mackay IR, Gershwin ME. The nature of autoimmune disease. Semin Liver Dis 1997;17:3-11.
(Abstract)
Mackay IR, Morris PJ. Association of autoimmune chronic hepatitis with HLA-A1-B8. Lancet
1972;2:793-5. (Abstract)
Mackay IR, Tait BD. HLA association with autoimmune type chronic active hepatitis:
identification of B8-DRw3 haplotype by family studies. Gastroenterology 1980;79:95-8. (Abstract)
Manns M, Gerken G, Kyriatsoulis A, et al. Characterisation of a new subgroup of autoimmune
chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet
1987;1:292-4. (Abstract)
Manns M, Gerken G, Trautwein C, et al. Characterization of primary biliary cirrhosis (PBC)
specific mitochondrial determinants by immunoblotting. Dtsch Z Verdau
Stoffwechselkr 1987;47:59-66. (Abstract)
Manns M, Meyer Zum Buschenfelde KH. A mitochondrial antigen-antibody system in
cholestatic liver disease detected by radioimmunoassay. Hepatology 1982;2:1-7.
(Abstract)
Manns M, Meyer Zum Büschenfelde KH, Slusarczyk J, et al. Detection of liver-kidney
microsomal autoantibodies by radioimmunoassay and their relation to
504  Hepatology 2012
antimitochondrial antibodies in inflammatory liver disease. Clin. Exp. Immunol.
1984;54:600-8. (Abstract)
Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation - when non-self
becomes self. Hepatology 2000;32:868-70. (Abstract)
Manns MP, Bremm A, Schneider PM, et al. HLA DRw8 and complement C4 deficiency as risk
factors in primary biliary cirrhosis. Gastroenterology 1991;101:1367-73. (Abstract)
Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear
sequence in P450IID6, a cytochrome P-450 monooxygenase. J. Clin. Invest.
1991;88:1370-8. (Abstract)
Manns MP, Jentzsch M, Mergener K, et al. Discordant manifestation of LKM-1 antibody positive
autoimmune hepatitis in identical twins. Hepatology 1990;12:840.
Manns MP, Johnson EF, Griffin KJ, et al. Major antigen of liver kidney microsomal antibodies in
idiopathic autoimmune hepatitis is cytochrome P450db1. J. Clin. Invest.
1998;83:1066-72. (Abstract)
Manns MP, Kruger M. Immunogenetics of chronic liver diseases. Gastroenterology
1994;106:1676-97. (Abstract)
Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology
2001;120:1502-17. (Abstract)
Mattalia A, Luttig B, Rosina F, et al. Persistence of autoantibodies against recombinant
mitochondrial and nuclear pore proteins after orthotopic liver transplantation for
primary biliary cirrhosis. J Autoimmun 1997;10:491-7. (Abstract)
Mehal Wz, Gregory Wl, Lo YM, et al. Defining the immunogenetic susceptibility to primary
biliary cirrhosis. Hepatology 1994;20:1213-9. (Abstract)
Milkiewicz P, Hubscher Sg, Skiba G et al. Recurrence of autoimmune hepatitis after liver
transplantation. Transplantation 1999;68:253-6. (Abstract)
Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in
primary sclerosing cholangitis. Gastroenterology 2001;121:900-7. (Abstract)
Mitchison HC, Palmer JM, Bassendine MF, et al. A controlled trial of prednisolone treatment in
primary biliary cirrhosis. Three-year results. J Hepatol 1992;15:336-44. (Abstract)
Moteki S, Leung PS, Dickson ER, et al. Epitope mapping and reactivity of autoantibodies to the
E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis
using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 1996;23:436-44. (Abstract)
Muratori L, Cataleta M, Muratori P, et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting:
comparison of different techniques. J. Immunol. Meth. 1995;187:259-64. (Abstract)
Muratori L, Sztul E, Muratori P, et al. Distinct epitopes on formiminotransferase cyclodeaminase
induce autoimmune liver cytosol antibody type 1. Hepatology 2001;34:494-501.
(Abstract)
Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese
patients with type 1 autoimmune hepatitis [see comments]. J Gastroenterol Hepatol
1998;13:490-5. (Abstract)
Neuberger J, Portmann B, Calne R, et al. Recurrence of autoimmune chronic active hepatitis
following orthotopic liver grafting. Transplantation 1984;37:363-365. (Abstract)
Newton Jl, Burt AD, Park JB, et al. Autoimmune hepatitis in older patients. Age Ageing
1997;26:441-4. (Abstract)
Nickowitz RE, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize
a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein
Gp210. J Exp Med 1993;178:2237-42. (Abstract)
Nickowitz RE, Wozniak RW, Schaffner F, et al. Autoantibodies against integral membrane
proteins of the nuclear envelope in patients with primary biliary cirrhosis.
Gastroenterology 1994;106:193-9. (Abstract)
Nishio A, Van De Water J, Leung PS, et al. Comparative studies of antimitochondrial
autoantibodies in sera and bile in primary biliary cirrhosis. Hepatology 1997;25:1085-9. (Abstract)
Nishioka M, Morshed SA, Kono K, et al. Frequency and significance of antibodies to P450IID6
protein in Japanese patients with chronic hepatiis C. J. Hepatol. 1997;26:992-1000.
(Abstract)
Nishioka M, Morshed SA, Mcfarlane IG. Geographical variation in the frequency and
characteristics of autoimmune liver diseases. Elsevier, Amsterdam. 1998.
Alcoholic Hepatitis  505
Notghi A, Nestle U, Rittner G, et al. Chromosomal aberrations in patients with primary biliary
cirrhosis. Hum Genet 1990;85:546-50. (Abstract)
Obermayer-Straub P, Perheentupa J, Braun S, et al. Hepatic autoantigens in patients with
autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
Gastroenterology 2001;121:668-77. (Abstract)
Okolicsanyi L, Fabris L, Viaggi S, et al. Primary sclerosing cholangitis: clinical presentation,
natural history and prognostic variables: an Italian multicentre study. The Italian PSC
Study Group. Eur J Gastroenterol Hepatol 1996;8:685-91. (Abstract)
Olsson R, Boberg KM, De Muckadell OS, et al. High-dose ursodeoxycholic acid in primary
sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Gastroenterology 2005;129:1464-72. (Abstract)
Onishi S, Sakamaki T, Maeda T, et al. DNA typing of HLA class II genes; DRB1*0803 increases
the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 1994;21:1053-60.
(Abstract)
Ota M, Seki T, Kiyoshawa K, et al. A possible association between basic amino acids of
position 13 of DRB1 chains and autoimmune hepatitis. Immunogenetics 1992;36:40-55. (Abstract)
Palmer JM, Jones DE, Quinn J, et al. Characterization of the autoantibody responses to
recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary
biliary cirrhosis. Hepatology 1999;30:21-6. (Abstract)
Palmer JM, Yeaman SJ, Bassendine MF, et al. M4 and M9 autoantigens in primary biliary
cirrhosis--a negative study. J Hepatol 1993;18:251-4. (Abstract)
Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune
hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology
1999;30:1374-80. (Abstract)
Pardi DS, Loftus Jr EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent
in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology
2003;124:889-93. (Abstract)
Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of
action and therapeutic use revisited. Hepatology 2002;36:525-31. (Abstract)
Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl
transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994;344:578-81.
(Abstract)
Pitkanen J, Vahamurto P, Krohn K, et al. Subcellular localization of the autoimmune regulator
protein. characterization of nuclear targeting and transcriptional activation domain. J
Biol Chem 2001;276:19597-602. (Abstract)
Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing
cholangitis and prognostic value of cholangiography in a Dutch population. Gut
2002;51:562-6. (Abstract)
Poupon RE, Huet PM, Poupon R, et al. A randomized trial comparing colchicine and
ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis.
UDCA-PBC Study Group. Hepatology 1996;24:1098-1103. (Abstract)
Poupon RE, Lindor KD, Cauch-Dudek K. Combined analysis of randomized controlled trials of
ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90
(Abstract)
Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with
ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol
2003;39:12-6. (Abstract)
Prados E, Cuervas-Mons V, De La Mata M, et al. Outcome of autoimmune hepatitis after liver
transplantation. Transplantation 1998;66:1645-50. (Abstract)
Raedsch R, Stiehl A, Walker S, et al. Combined ursodeoxycholic acid plus colchicine--treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind
study. Z Gastroenterol 1992;30 Suppl 1:55-7. (Abstract)
Ramsey C, Winqvist O, Puhakka L, et al. Aire deficient mice develop multiple features of
APECED phenotype and show altered immune response. Hum Mol Genet
2002;11:397-409. (Abstract)
Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for
autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol
1999;30:131-41. (Abstract)
506  Hepatology 2012
Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation
is more effective than resection for hilar cholangiocarcinoma. Ann Surg
2005;242:451-458; discussion 458-61. (Abstract)
Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, et al. Deflazacort for long-term
maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig
1999;91:630-8. (Abstract)
Reynoso-Paz S, Leung PS, Van De Water J, et al. Evidence for a locally driven mucosal
response and the presence of mitochondrial antigens in saliva in primary biliary
cirrhosis. Hepatology 2000;31:24-9. (Abstract)
Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in
autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol
2000;33:371-5. (Abstract)
Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other
disorders. Clin. Exp. Immunol. 1973;15:331-44. (Abstract)
Rost D, Rudolph G, Kloeters-Plachky P, et al. Effect of high-dose ursodeoxycholic acid on its
biliary enrichment in primary sclerosing cholangitis. Hepatology 2004;40:693-8.
(Abstract)
Sanchez-Urdazpal L, Czaja AJ, Van Holk B. Prognostic features and role of liver transplantation
in severe corticoid-treated autoimmune chronic active hepatitis. Hepatology
1991;15:215-21. (Abstract)
Schüler A, Manns MP. Treatment of autoimmune hepatitis. In: Arroyo V, Bosch J, Rodés J
(eds) Treatment in Hepatology. Masson, S.A., Paris, p 375-83. 1995.
Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of
colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Hepatology 2003;38:203-9. (Abstract)
Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological
remission of severe chronic active liver disease: a controlled study of treatments and
early prognosis. Gastroenterology 1972;63:820-33. (Abstract)
Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas
antibodies in autoimmune hepatitis. Hepatology 1993;18:1-9. (Abstract)
Sternsdorf T, Guldner HH, Szostecki C, et al. Two nuclear dot-associated proteins, PML and
Sp100, are often coautoimmunogenic in patients with primary biliary cirrhosis. Scand
J Immunol 1995;42:257-68. (Abstract)
Strassburg CP, Alex B, Zindy F, et al. Identification of cyclin A as a molecular target of
antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J
Hepatol 1996;25:859-66. (Abstract)
Strassburg CP, Jaeckel E, Manns MP. Anti-mitochondrial antibodies and other immunological
tests in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:595-601.
(Abstract)
Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin
Liver Dis 2002;22:339-352. (Abstract)
Strassburg CP, Manns MP. Autoimmune hepatitis versus viral hepatitis C. Liver 1995;15:225-32. (Abstract)
Strassburg CP, Manns MP. Autoimmune tests in primary biliary cirrhosis. Baillieres Best Pract
Res Clin Gastroenterol 2000;14:585-99. (Abstract)
Strassburg CP, Manns MP. Primär biliäre Zirrhose und primär sklerosierende Cholangitis.
Internistische Praxis 1996;36:57-74.
Strassburg CP, Manns MP. Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and
therapy. Internist (Berl) 2004;45:16-26. (Abstract)
Strassburg CP, Obermayer-Straub P, Alex B, et al. Autoantibodies against
glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis.
Gastroenterology 1996;111:1576-86. (Abstract)
Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in hepatitis C and D virus
infection. J. Viral. Hepat. 1996;3:49-59. (Abstract)
Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev
Allergy Immunol 2000;18:127-39. (Abstract)
Strettell MD, Thomson LJ, Donaldson PT, et al. HLA-C genes and susceptibility to type 1
autoimmune hepatitis. Hepatology 1997;26:1023-6. (Abstract)
Sudan D, Deroover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant
2002;2:774-9. (Abstract)
Alcoholic Hepatitis  507
Sugimura T, Obermayer-Straub P, Kayser A, et al. A major CYP2D6 autoepitope in
autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure
homologous to other cytochrome P450 autoantigens. Autoimmunity 2002;35:501-13.
(Abstract)
Szostecki C, Krippner H, Penner E, et al. Autoimmune sera recognize a 100 kD nuclear protein
antigen (sp-100). Clin Exp Immunol 1987;68:108-16. (Abstract)
Szostecki C, Will H, Netter HJ, et al. Autoantibodies to the nuclear Sp100 protein in primary
biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin
class distribution. Scand J Immunol 1992;36:555-64. (Abstract)
Tan EM, Chan EKL, Sullivan KF, et al. Antinuclear antibodies (ANAs): diagnostically specific
immune markers and clues toward the understanding of systemic autoimmunity. Clin.
Immunol. Immunopathol. 1998;47:121-41. (Abstract)
Terjung B, Spengler U, Sauerbruch T, et al. "Atypical p-ANCA" in IBD and hepatobiliary
disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and
myeloid cell lines. Gastroenterology 2000;119:310-22. (Abstract)
Tillmann Hl, Jackel E, Manns MP. Liver transplantation in autoimmune liver disease--selection
of patients. Hepatogastroenterology 1999;46:3053-9. (Abstract)
Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273
patients with primary sclerosing cholangitis: A single center study. Am J
Gastroenterol 2007;102:107-14. (Abstract)
Tischendorf JJ, Meier PN, Strassburg CP, et al. Characterization and clinical course of
hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J
Gastroenterol 2006;41:1227-34. (Abstract)
Treichel U, Poralla T, Hess G, et al. Autoantibodies to human asialoglycoprotein receptor in
autoimmune-type chronic hepatitis. Hepatology 1990;11:606-12. (Abstract)
Tsuji K, Watanabe Y, Van De Water J, et al. Familial primary biliary cirrhosis in Hiroshima. J
Autoimmun 1999;13:171-8. (Abstract)
Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and
regulation in the gastrointestinal tract. Mol Pharmacol 2001;59:405-14. (Abstract)
Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of
colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Ann Intern Med 2001;134:89-95. (Abstract)
Uibo R, Salupere V. The epidemiology of primary biliary cirrhosis: immunological problems.
Hepatogastroenterology 1999;46:3048-52. (Abstract)
Van De Water J, Gershwin Me, Leung P, et al. The autoepitope of the 74-kD mitochondrial
autoantigen of primary biliary cirrhosis corresponds to the functional site of
dihydrolipoamide acetyltransferase. J Exp Med 1988;167:1791-9. (Abstract)
Van De Water J, Shimoda S, Niho Y, et al. The role of T cells in primary biliary cirrhosis. Semin
Liver Dis 1997;17:105-13. (Abstract)
Van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al. Budesonide or prednisone in combination
with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group [see comments]. Am J
Gastroenterol 2000;95:2015-22. (Abstract)
Van Norstrand MD, Malinchoc M, Lindor KD, et al. Quantitative measurement of autoantibodies
to recombinant mitochondrial antigens in patients with primary biliary cirrhosis:
relationship of levels of autoantibodies to disease progression. Hepatology
1997;25:6-11. (Abstract)
Van Steenbergen W, Sciot R, Van Eyken P, et al. Combined treatment with methotrexate and
ursodeoxycholic acid in non-cirrhotic primary biliary cirrhosis. Acta Clin Belg
1996;51:8-18. (Abstract)
Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: A potential new treatment for autoimmune
chronic active hepatitis: results of an open-label preliminary trial. Am. J.
Gastroenterol. 1995;90:771-6. (Abstract)
Vento S, Cainelli F, Ferraro T, et al. Autoimmune hepatitis type 1 after measles. Am. J.
Gastroenterol. 1996;91:2618-20. (Abstract)
Vento S, Cainelli F, Renzini C, et al. Autoimmune hepatitis type 2 induced by HCV and
persisting after viral clearance. Lancet 1997;350:1298-9. (Abstract)
Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for
autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet
1991;337:1183-7. (Abstract)